Literature DB >> 19962579

The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline.

Nadine Shehata1, Valerie Palda, Tom Bowen, Elie Haddad, Thomas B Issekutz, Bruce Mazer, Robert Schellenberg, Richard Warrington, David Easton, David Anderson, Heather Hume.   

Abstract

The standard treatment for patients with primary antibody deficiency is immunoglobulin (IG), but the care of these patients is complex. These guidelines, initiated by the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products, have been developed to facilitate and standardize the care of these patients by the various physician specialties that are responsible for their care. A panel of national expert immunologists and methodologists developed salient clinical questions; and a systematic, expert, and bibliography literature search up to July 2008 was conducted. One thousand eighty-seven citations were retrieved, and 102 reports were used in the preparation of this guideline. The recommendations provide guidance (1) on the complexity of the treatment of these patients; (2) the established benefits of IG on morbidity and mortality; (3) dosage, routes of administration, and management of reactions; (4) the various IG formulations available; (5) vaccination of these patients; and (6) research priorities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19962579     DOI: 10.1016/j.tmrv.2009.09.011

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  28 in total

Review 1.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

2.  Personalized IgG Replacement Therapy for Patients with B cell Inborn Errors of Immunity.

Authors:  Vincent R Bonagura
Journal:  J Clin Immunol       Date:  2021-03-19       Impact factor: 8.317

3.  Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.

Authors:  Raffaella Viti; Andrea Marcellusi; Alessandro Capone; Andrea Matucci; Alessandra Vultaggio; Claudio Pignata; Giuseppe Spadaro; Angelo Vacca; Carolina Marasco; Carlo Agostini; Francesco Saverio Mennini
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

4.  Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

Authors:  Jeffrey S Stonebraker; Albert Farrugia; Benjamin Gathmann; Jordan S Orange
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 5.  A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Authors:  S Lachance; A L Christofides; J K Lee; L H Sehn; B C Ritchie; C Shustik; D A Stewart; C L Toze; E Haddad; D C Vinh
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

6.  Immunologic phenotype of a child with the MEHMO syndrome.

Authors:  I Trochanová; D Staníková; M Škopková; K Haštová; D Gašperíková; J Staník; P Čižnár
Journal:  Physiol Res       Date:  2020-09-09       Impact factor: 1.881

7.  Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States.

Authors:  Faith Huang; Elizabeth Feuille; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2012-09-08       Impact factor: 8.317

Review 8.  Primary Immunodeficiencies: Diseases of Children and Adults - A Review.

Authors:  Aleksandra Lewandowicz-Uszyńska; Gerard Pasternak; Jerzy Świerkot; Katarzyna Bogunia-Kubik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.

Authors:  Huifang Lu; Anna S Lok; Carla L Warneke; Sairah Ahmed; Harrys A Torres; Fernando Martinez; Maria E Suarez-Almazor; Jessica T Foreman; Alessandra Ferrajoli; Jessica P Hwang
Journal:  Lancet Haematol       Date:  2018-10       Impact factor: 18.959

Review 10.  Local and national advocacy support.

Authors:  Ralph S Shapiro; Marcia Boyle; Elena E Perez
Journal:  J Clin Immunol       Date:  2012-07-19       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.